NovaBay Pharmaceuticals’ Avenova Allograft is Launched in the United States

NovaBay Pharmaceuticals announced the launch of the Avenova Allograft in the United States through its physician-dispensed channel. The company’s prescription optic allograft, which is intended for use as a protective covering during the repair of ocular surfaces, is manufactured using BioStem Technologies’ process.

The product launch follows a previously announced agreement under which NovaBay was granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft under the Avenova brand. The Avenova allograft will be offered in the global ophthalmology amniotic membrane market.

According to the company, the Avenova Allograft provides a protective environment or covering for repair of the cornea and conjunctiva, helping ocular surface to return to a healthier state. Using its 'six-step BioRetain process' that preserves the natural integrity of the placental tissue, BioStem Technologies will be responsible for manufacturing, packaging, shipping, and regulatory compliance.

NovaBay advised that the product is composed only of the amnion layer of the placental membrane with a thickness of 20-50 µm, which makes it suitable for delicate ophthalmic applications. The Avenova Allograft is available in 8-, 10-, and 12-mm diameter sizes.

NovaBay’s commercial launch of the Avenova Allograft includes outreach programs aimed at educating eyecare specialists on both the clinical benefits of the product, as well as the process for Medicare reimbursement.

In addition to the new allograft product, NovaBay’s Avenova suite of products includes Avenova antimicrobial lid and lash spray, specially designed dry wipes, lubricating eye drops, a warm eye compress, oral supplements, and the i-Chek mirror to monitor physical eyelid health, stated the company.